Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Anti-inflammatory and antileukemia potential of myrciaria Sp. ethanol extract

Joint Event on 4th European Biopharma Congress & 6th International Conference and Exhibition on Pharmacology and Ethnopharmacology

M�¡rcia Goettert, Shanna Bitencourt, Diorge Marmitt, Stefani Stoll, Bruna Caye, Juliana Dorr, Jarbas Oliveira and Stefan Laufer

Univates, Lajeado, Brazil Pontifical Catholic University of Rio Grande do Sul, Brazil University of T�¼bingen, Germany

Posters & Accepted Abstracts: Clin Pharmacol Biopharm

DOI: 10.4172/2167-065X-C1-026

Abstract
Most anti-inflammatory and anticancer drugs produced are derived from naturally occurring compounds or their derivatives. There is a constant search for new metabolites from natural origin, particularly from plants, which have potential for efficacious drugs. Myrtaceae, a plant family present in tropical areas, is one of the most studied on biological activities. Myrciaria genus belongs to this family and comprises several species; however, few studies have shown their therapeutic potential. The present study aimed to investigate the anti- inflammatory potential and cytotoxicity of the ethanol extract of a species of the Myrciaria genus on RAW 267.4 macrophage cells, human peripheral blood mononuclear cells (PBMCs) and Jurkat acute T-lymphocytic leukemia cells. First, RAW 267.4 and PBMCs were treated with increasing concentrations of the extract to assess cytotoxicity for 48 h and 96 h using Alamar blue and Trypan blue exclusion, respectively. In addition, lymphoproliferation was assayed on phytohemagglutinin (PHA)stimulated PBMCs using MTT method. TNF-�± levels were determined by ELISA after RAW 267.4 and PBMCs were pre-incubated with the extract and then challenged with LPS. Protein expression of inflammation-associated markers (NF-kB, p38�± and p-p38) in LPS-activated RAW 264.7 cells was assessed by Western blot. In addition, the extract was screened for p38 MAPK inhibition using cell-free enzyme activity assay. Later, Jurkat cells were challenged for 24 h with the extract and cytotoxicity was determined by Trypan blue exclusion. After challenging RAW 264.7 and PBMCs with Myrciaria sp. extract, a slight decrease (p<0.05) on RAW 264.7 viability was observed with the maximum concentration tested (200 �¼g/mL), while PBMCs were not affected by the extract. However, PHA-stimulated PBMCs had a decreased proliferation when cultured with 200 �µg/mL extract. In addition, when both LPSactivated cells were pre- treated with the extract, there were dose-dependent decrease in TNF-�± levels (p<0.001), suggesting possible immunomodulatory and anti-inflammatory activities of the extract. Furthermore, Western blotting on RAW 264.7 cells showed that the extract was capable to inhibit LPS-induced NF-kB activation and p38 phosphorylation. Besides, Myrciaria sp. extract presented a great p38 inhibitory activity. On Jurkat cells, the ethanol extract showed cytotoxicity after 24 h, indicating a selectivity. The IC50 of the extract was 127.7 �µg/mL. The results suggest that Myrciaria sp. ethanol extract present great biological and is a potent inhibitor of p38 MAPK suggesting an action mechanism with selective activity that can be used in the development of anti-inflammatory and antileukemic drugs or phytomedicines.
Biography
Top